Cancer

Aida Pharmaceuticals Initiates Preclinical Research of Potential Anti-Cancer Treatment Vasostatin-Apo2L

Published in Drug Week, March 30th, 2007

Aida Pharmaceuticals, Inc. (BULLETIN BOARD: AIDA) , one of mainland China's leading pharmaceutical companies, announced the Company's subsidiary, Shanghai Qiaer Biotechnology, has initiated preclinical research of the potential anti- cancer treatment Vasostatin-Apo2L.

Vasostatin-Apo2L is a recombinant fusion protein with the potential to inhibit tumor growth. The treatment may integrate the function of an extracted fragment of Vasostatin, an inhibitor of angiogenesis and tumor growth with similar results of Rh-Apo2L, the Company's existing anti-cancer treatment currently in Phase II trials, which induces the apoptosis (cellular death) of cancer cells. Scientists from...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2007-03-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry